Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Sibeprenlimab by Visterra for IgA Nephropathy (Berger's Disease): Likelihood of Approval
Sibeprenlimab is under clinical development by Visterra and currently in Phase III for IgA Nephropathy (Berger's Disease). According to GlobalData,...
VIS-171 by Visterra for Autoimmune Disorders: Likelihood of Approval
VIS-171 is under clinical development by Visterra and currently in Phase I for Autoimmune Disorders. According to GlobalData, Phase I...
VIS-954 by Visterra for Transplant Rejection: Likelihood of Approval
VIS-954 is under clinical development by Visterra and currently in Phase I for Transplant Rejection. According to GlobalData, Phase I...
VIS-954 by Visterra for Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis): Likelihood of Approval
VIS-954 is under clinical development by Visterra and currently in Phase I for Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis). According...
Sibeprenlimab by Visterra for IgA Nephropathy (Berger's Disease): Likelihood of Approval
Sibeprenlimab is under clinical development by Visterra and currently in Phase III for IgA Nephropathy (Berger's Disease). According to GlobalData,...